Advances in Lung Cancer

Volume 10, Issue 3 (September 2021)

ISSN Print: 2169-2718   ISSN Online: 2169-2726

Google-based Impact Factor: 0.17  Citations  

Impact of Preoperative Serum Tumor Markers in Patients with Lung Squamous Cell Carcinoma

HTML  XML Download Download as PDF (Size: 466KB)  PP. 48-55  
DOI: 10.4236/alc.2021.103005    209 Downloads   844 Views  

ABSTRACT

Background: Several previous researchers have investigated the prognostic value of serum tumor markers, especially carcinoembryonic antigen (CEA). Only a limited number of studies reported the usefulness of serum tumor markers for lung squamous cell carcinoma (SQ). We aimed to examine the significance of serum tumor markers for lung SQ. Methods: Eighty-five lung SQ patients who underwent surgery and followed more than 5-year were included. The ratios of 5-year survivors to all patients in groups with several clinicopathologic factors, including tumor markers, were compared. We also compared the clinicopathologic factors between central type and peripheral type SQ. Results: The majority of patients were male gender and current/ former smokers. Age, pN status, cytokeratin-19 fragment (CYFRA 21-1), squamous cell carcinoma antigen (SCC), and comorbid interstitial pneumonia (IP) were associated with the ratio of 5-year survivors significantly. When patients were compared based on tumor location, high p-stage and CYFRA 21-1 were related to central type SQ. Conclusion: Both SCC and CYFRA 21-1 appeared to be useful prognostic markers for patients with lung SQ. Furthermore, CYFRA 21-1 was related to central type SQ.

Share and Cite:

Tomita, M. , Kuroki, S. , Hamahiro, T. , Maeda, R. and Ayabe, T. (2021) Impact of Preoperative Serum Tumor Markers in Patients with Lung Squamous Cell Carcinoma. Advances in Lung Cancer, 10, 48-55. doi: 10.4236/alc.2021.103005.

Cited by

No relevant information.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.